Author:
Jiang Junjun,Xu Xi,Guo Wenqin,Su Jinming,Huang Jiegang,Liang Bingyu,Chen Hui,Zang Ning,Liao Yanyan,Ye Li,Liang Hao
Funder
National Natural Science Foundation of China
Scientific Research Foundation of the Higher Education Institutions of Guangxi Province, China
Guangxi scientific research and technology development program fund
Guangxi Universities 100-Talent Program, Guangxi, China
Universities Innovation Research Team and Outstanding Scholar Program
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Virology,Molecular Medicine
Reference34 articles.
1. International C. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva Switzerland Unaids. 2013;(7):553–6.
2. Buzon MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, et al. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther. 2008;13:881–93.
3. Blanco JL, Martinez-Picado J. HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS. 2012;7:415–21.
4. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201:814–22.
5. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63:96–100.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献